Other equities research analysts have also issued reports about the stock. Oppenheimer decreased their target price on shares of Intercept Pharmaceuticals from to in a research note on Wednesday, February 26th. Wells Fargo & Co reiterated an overweight rating and set a $146.00 target price (up from $120.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. SVB Leerink reiterated an underperform rating on shares of Intercept Pharmaceuticals in a research note on Thursday, January 2nd. Cantor Fitzgerald reiterated a buy rating and set a $186.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Bank of America initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, March 5th. They set a neutral rating and a $111.00 target price for the company. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $146.53.
NASDAQ ICPT traded up $4.10 during mid-day trading on Thursday, reaching $62.85. The stock had a trading volume of 611,816 shares, compared to its average volume of 595,155. Intercept Pharmaceuticals has a 1 year low of $47.57 and a 1 year high of $125.00. The stock has a market cap of $1.93 billion, a PE ratio of -5.77 and a beta of 1.77. The company has a fifty day moving average price of $78.90 and a 200 day moving average price of $88.36. The company has a debt-to-equity ratio of 10.32, a current ratio of 4.45 and a quick ratio of 4.45.
In related news, insider Jason Campagna sold 732 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $113.02, for a total value of $82,730.64. Following the completion of the transaction, the insider now owns 6,303 shares of the company’s stock, valued at approximately $712,365.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christian Weyer sold 723 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $94.04, for a total transaction of $67,990.92. Following the completion of the transaction, the executive vice president now directly owns 18,560 shares of the company’s stock, valued at approximately $1,745,382.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,568 shares of company stock valued at $160,623. Insiders own 5.00% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC bought a new position in Intercept Pharmaceuticals in the 3rd quarter worth $36,000. Edge Wealth Management LLC bought a new position in Intercept Pharmaceuticals in the 4th quarter worth $37,000. Nisa Investment Advisors LLC boosted its holdings in Intercept Pharmaceuticals by 200.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 300 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 200 shares during the period. Kistler Tiffany Companies LLC boosted its holdings in Intercept Pharmaceuticals by 33.3% in the 4th quarter. Kistler Tiffany Companies LLC now owns 400 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 100 shares during the period. Finally, Sowell Financial Services LLC boosted its holdings in Intercept Pharmaceuticals by 469.6% in the 4th quarter. Sowell Financial Services LLC now owns 655 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 540 shares during the period. 78.66% of the stock is owned by institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Recommended Story: How much money do you need to begin day trading?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.